A statement released earlier today by Scotia Capital about Jean Coutu Group (TSE:PJC.A) bumps the target price to $19.00
- Updated: September 29, 2016
Scotia Capital bumped up the target of Jean Coutu Group (TSE:PJC.A) to $19.00 stating a potential downside of -0.05%.
On 9/28/2016, RBC Capital Markets released a statement on Jean Coutu Group (TSE:PJC.A) bumped up the target price from $19.00 to $20.00 that suggested an upside of 0.00%.
Boasting a price of $20.09, Jean Coutu Group (TSE:PJC.A) traded 0.00% even on the day. With the last close up 0.00% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Jean Coutu Group has recorded a 50-day average of $0.00 and a two hundred day average of $0.00. Volume of trade held steady, with 0 shares of PJC.A changing hands on par with the typical 0
With a total market value of $0, Jean Coutu Group has with a one year low of $0.00 and a one year high of $0.00 .
More About Jean Coutu Group (TSE:PJC.A)
The Jean Coutu Group (PJC) Inc. is a Canada-based company, which is engaged in franchising pharmacy chains. The Company operates through two segments: franchising and generic drugs. Within the franchising segment, the Company carries on the franchising activity under the banners of PJC Jean Coutu, PJC Clinique, PJC Jean Coutu Sante and PJC Jean Coutu Sante Beaute; operates approximately two distribution centers, and coordinates various other services for its franchisees. In the generic drugs segment, the Company owns Pro Doc Ltd, a Canadian manufacturer of generic drugs whose revenues come from the sale of generic drugs to wholesalers and pharmacists. The Company has approximately 420 PJC franchised stores in Quebec, Ontario and New Brunswick. The Company's services to its franchisees include centralized purchasing, distribution, marketing, training, human resources, management, operational consulting and information systems, as well as a private label program.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.